Grifols (GRFS) Competitors $7.51 -0.21 (-2.72%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GRFS vs. TEVA, BGNE, UTHR, VTRS, RPRX, SMMT, GMAB, INSM, BMRN, and RDYShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), United Therapeutics (UTHR), Viatris (VTRS), Royalty Pharma (RPRX), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Insmed (INSM), BioMarin Pharmaceutical (BMRN), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry. Grifols vs. Teva Pharmaceutical Industries BeiGene United Therapeutics Viatris Royalty Pharma Summit Therapeutics Genmab A/S Insmed BioMarin Pharmaceutical Dr. Reddy's Laboratories Teva Pharmaceutical Industries (NYSE:TEVA) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations. Which has more risk and volatility, TEVA or GRFS? Teva Pharmaceutical Industries has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Does the MarketBeat Community believe in TEVA or GRFS? Teva Pharmaceutical Industries received 978 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 67.81% of users gave Teva Pharmaceutical Industries an outperform vote while only 56.02% of users gave Grifols an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes132767.81% Underperform Votes63032.19% GrifolsOutperform Votes34956.02% Underperform Votes27443.98% Do insiders and institutionals hold more shares of TEVA or GRFS? 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is TEVA or GRFS more profitable? Grifols has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -5.73%. Teva Pharmaceutical Industries' return on equity of 42.92% beat Grifols' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-5.73% 42.92% 7.25% Grifols N/A N/A N/A Is TEVA or GRFS a better dividend stock? Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 4.6%. Grifols pays an annual dividend of $0.36 per share and has a dividend yield of 4.8%. Teva Pharmaceutical Industries pays out -118.9% of its earnings in the form of a dividend. Grifols pays out 37.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Do analysts rate TEVA or GRFS? Teva Pharmaceutical Industries currently has a consensus target price of $20.88, indicating a potential downside of 5.50%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Grifols 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Does the media favor TEVA or GRFS? In the previous week, Teva Pharmaceutical Industries had 19 more articles in the media than Grifols. MarketBeat recorded 27 mentions for Teva Pharmaceutical Industries and 8 mentions for Grifols. Teva Pharmaceutical Industries' average media sentiment score of 0.54 beat Grifols' score of 0.44 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 10 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, TEVA or GRFS? Grifols has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.77B1.49-$559M-$0.85-25.99Grifols$7.01B0.74$64.20M$0.977.74 SummaryTeva Pharmaceutical Industries beats Grifols on 15 of the 21 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.16B$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio7.7410.5989.9717.18Price / Sales0.74195.801,116.21116.99Price / Cash9.7757.1642.8937.86Price / Book0.605.094.784.78Net Income$64.20M$151.83M$120.23M$225.60M7 Day Performance2.46%-2.13%-1.92%-1.23%1 Month Performance-12.32%-3.10%11.49%3.36%1 Year Performance-28.34%11.54%30.57%16.60% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols3.4529 of 5 stars$7.51-2.7%N/A-28.3%$5.16B$7.01B7.7423,737Gap UpTEVATeva Pharmaceutical Industries1.8723 of 5 stars$16.72+1.3%$19.67+17.6%+108.5%$18.94B$16.77B-19.7937,851Analyst DowngradeOptions VolumeNews CoverageBGNEBeiGene2.6117 of 5 stars$176.52-1.6%$253.69+43.7%-0.3%$17.20B$2.46B-21.7710,600UTHRUnited Therapeutics4.7048 of 5 stars$370.95+2.5%$370.860.0%+64.7%$16.56B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsVTRSViatris2.0503 of 5 stars$12.74+0.9%$13.67+7.3%+17.6%$15.21B$15.05B-17.0738,000News CoverageRPRXRoyalty Pharma4.6397 of 5 stars$25.17+1.3%$41.67+65.5%-9.0%$14.83B$2.36B12.8780SMMTSummit Therapeutics3.2703 of 5 stars$18.21+2.1%$33.33+83.0%+650.8%$13.43B$700,000.00-63.68105News CoverageGap DownGMABGenmab A/S4.2395 of 5 stars$20.21+0.2%$45.20+123.7%-34.6%$13.37B$19.84B19.582,204Positive NewsHigh Trading VolumeINSMInsmed2.9718 of 5 stars$73.07+2.0%$83.67+14.5%+139.4%$13.07B$342.96M-12.91373Insider TradeBMRNBioMarin Pharmaceutical4.9845 of 5 stars$66.07+0.1%$94.20+42.6%-31.0%$12.59B$2.75B39.533,401Positive NewsRDYDr. Reddy's Laboratories1.8134 of 5 stars$14.76+2.1%$17.00+15.2%+15.1%$12.32B$299.87B22.9527,048Analyst DowngradeNews Coverage Related Companies and Tools Related Companies TEVA Alternatives BGNE Alternatives UTHR Alternatives VTRS Alternatives RPRX Alternatives SMMT Alternatives GMAB Alternatives INSM Alternatives BMRN Alternatives RDY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRFS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRFS Stock Alerts